Alector, Inc. Files Q2 2024 10-Q Report
Ticker: ALEC · Form: 10-Q · Filed: 2024-08-07T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotechnology, financials, collaboration
TL;DR
**ALECTOR Q2 10-Q FILED: Check financials & GSK collab updates.**
AI Summary
Alector, Inc. filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance and business operations. The filing details various financial statement line items and disclosures related to its research and development activities, including its collaboration with GSK. Specific dates and financial figures are embedded within the detailed tables and notes of the report.
Why It Matters
This filing provides investors with a detailed look at Alector's financial health and operational progress during the second quarter of 2024, including updates on its key drug development programs and partnerships.
Risk Assessment
Risk Level: medium — As a biotechnology company, Alector faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in the filing.
Key Numbers
- 2024-06-30 — Reporting Period End Date (The end of the fiscal quarter covered by the 10-Q.)
- 2024-08-07 — Filing Date (The date Alector, Inc. submitted this 10-Q to the SEC.)
Key Players & Entities
- Alector, Inc. (company) — Filer of the 10-Q report
- GSK (company) — Collaborator mentioned in financial disclosures
- Paula Hammond (person) — Mentioned in relation to financial reporting periods
- Sara Kenkare Mitra (person) — Mentioned in relation to Rule 10b5-1 trading plans
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period ending June 30, 2024.
Who is Alector, Inc. collaborating with, as mentioned in the filing?
Alector, Inc. is collaborating with GSK, as indicated by references to 'alec:GskMember'.
What is the company's primary industry classification?
Alector, Inc. is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
When was Alector, Inc. formerly known as Alector LLC?
The company was formerly known as Alector LLC, with a date of name change on September 15, 2015.
Are there any disclosures related to trading plans for company personnel?
Yes, the filing mentions 'alec:Rule10B51TradingPlanMember' in relation to Sara Kenkare Mitra.
From the Filing
0000950170-24-092814.txt : 20240807 0000950170-24-092814.hdr.sgml : 20240807 20240807161524 ACCESSION NUMBER: 0000950170-24-092814 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240807 DATE AS OF CHANGE: 20240807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 241183965 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 10-Q 1 alec-20240630.htm 10-Q 10-Q 456 Q2 false 558 456 0001653087 561 --12-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001653087 alec:GskMember srt:MaximumMember 2024-06-30 0001653087 us-gaap:RetainedEarningsMember 2023-06-30 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001653087 alec:GskMember 2024-04-01 2024-06-30 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001653087 alec:GskMember srt:MaximumMember 2021-07-01 0001653087 us-gaap:CommonStockMember 2023-12-31 0001653087 alec:GskMember 2023-07-01 2023-09-30 0001653087 alec:GskMember 2022-01-01 2022-01-31 0001653087 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001653087 alec:GskMember 2021-07-01 2021-07-01 0001653087 alec:CashEquivalentsAndMarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001653087 alec:PaulaHammondMember 2024-04-01 2024-06-30 0001653087 alec:SaraKenkareMitraMember alec:Rule10B51TradingPlanMember 2024-06-30 0001653087 2024-01-01 2024-03-31 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001653087 alec:CashEquivalentsAndMarketableSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001653087 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001653087 alec:AbbVieBiotechnologyLimitedMember 2024-06-30 0001653087 alec:GskMember 2023-04-01 2023-06-30 0001653087 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001653087 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001653087 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001653087 alec:AlectorMember 2024-01-01 2024-06-30 0001653087 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001653087 alec:KristineYaffeMember 2024-04-01 2024-06-30 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2024-01-01 2024-06-30 0001653087 2024-03-31 0001653087 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001653087 srt:MinimumMember alec:GskMember 2023-05-31 0001653087 2023-01-01 2023-06-30 0001653087 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001653087 us-gaap:OverAllotmentOptionMember 2024-01-19 0001653087 alec:RestrictedStockAwardsAndRestrictedStockUnitsMember 2023-01-01 2023-06-30 0001653087 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001653087 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001653087 2024-01-01 2024-06-30 0001653087 us-gaap:RetainedEarningsMember 2022-12-31 0001653087 alec:AbbVieBiotechnologyLimitedMember srt:MaximumMember 2023-02-01 2023-02-28 0001653087 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001653087 alec:GskMember 2023-12-31 0001653087 alec:CertificateOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001653087 alec:GskMember 2023-05-31 0001653087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 00